These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11429014)

  • 1. Fluconazole in transplant recipients: options and limitations.
    Strahilevitz J; Sugar AM; Engelhard D
    Transpl Infect Dis; 2000 Jun; 2(2):62-71. PubMed ID: 11429014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fluconazole era: management of hematogenously disseminated candidiasis in the nonneutropenic patient.
    Kramer KM; Skaar DJ; Ackerman BH
    Pharmacotherapy; 1997; 17(3):538-48. PubMed ID: 9165556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic evaluation of fluconazole in critically ill patients.
    Sinnollareddy M; Peake SL; Roberts MS; Playford EG; Lipman J; Roberts JA
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1431-40. PubMed ID: 21883033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fungal infections in patients undergoing bone marrow transplantation: an approach to a rational management protocol.
    Castagnola E; Bucci B; Montinaro E; Viscoli C
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():97-106. PubMed ID: 8932808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
    Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
    Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Micafungin for therapy of invasive candidiasis in solid organ transplant recipients].
    Fortún-Abete J
    Rev Iberoam Micol; 2009 Mar; 26(1):65-8. PubMed ID: 19463280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
    McCoy D; Depestel DD; Carver PL
    Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal agents for preventing fungal infections in solid organ transplant recipients.
    Playford EG; Webster AC; Sorell TC; Craig JC
    Cochrane Database Syst Rev; 2004; (3):CD004291. PubMed ID: 15266524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
    Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial.
    Winston DJ; Pakrasi A; Busuttil RW
    Ann Intern Med; 1999 Nov; 131(10):729-37. PubMed ID: 10577295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal prophylaxis in hematopoietic stem cell transplant recipients.
    Marr KA
    Oncology (Williston Park); 2001 Nov; 15(11 Suppl 9):15-9. PubMed ID: 11757846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis.
    Shorr AF; Chung K; Jackson WL; Waterman PE; Kollef MH
    Crit Care Med; 2005 Sep; 33(9):1928-35; quiz 1936. PubMed ID: 16148461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
    Charlier C; Hart E; Lefort A; Ribaud P; Dromer F; Denning DW; Lortholary O
    J Antimicrob Chemother; 2006 Mar; 57(3):384-410. PubMed ID: 16449304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Level of evidence for therapeutic drug monitoring of fluconazole].
    Venisse N; Le Guellec C
    Therapie; 2011; 66(2):97-101. PubMed ID: 21635855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi].
    Salavert-Lletí M; Zaragoza-Crespo R
    Rev Iberoam Micol; 2009 Mar; 26(1):81-9. PubMed ID: 19463284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
    Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplantation recipients.
    Gubbins PO; Bowman JL; Penzak SR
    Pharmacotherapy; 1998; 18(3):549-64. PubMed ID: 9620106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia.
    Preston SL; Briceland LL
    Am J Health Syst Pharm; 1995 Jan; 52(2):164-73; quiz 205-6. PubMed ID: 12879543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.
    Goa KL; Barradell LB
    Drugs; 1995 Oct; 50(4):658-90. PubMed ID: 8536553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.